Who owns BioMarin?
|Founders||Christopher Starr, Ph.D. Grant W. Denison Jr.|
|Headquarters||San Rafael, California, U.S.|
|Key people||Jean-Jacques Bienaimé (Chairman & CEO) Daniel Spiegelman (Executive VP & CFO) Brian R. Mueller (Senior VP, Finance & CAO)|
Is BioMarin a good place to work?
Is BioMarin Pharmaceutical a good company to work for? BioMarin Pharmaceutical has an overall rating of 4 out of 5, based on over 542 reviews left anonymously by employees. 78% of employees would recommend working at BioMarin Pharmaceutical to a friend and 70% have a positive outlook for the business.
Where is BioMarin headquarters?
Novato, CABioMarin Pharmaceutical / HeadquartersNovato is a city in Marin County, California, in the North Bay region of the Bay Area. At the 2020 census, Novato had a population was 53,225. Wikipedia
Where is BioMarin?
Our headquarters and original manufacturing facilities are located just north of San Francisco in Marin County. Located in downtown San Rafael, our corporate headquarters has a campus-like feel with multiple buildings joined by meandering green walkways with the San Francisco Bay and Mount Tamalpais in the background.
What does BioMarin pharmaceutical do?
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.
What does BioMarin Pharmaceutical Inc do?
Pioneers in Rare Disease Established in 1997, BioMarin is a world leader in developing and commercializing first- or best-in-class therapies for rare genetic diseases.
What do BioMarin do?
Whats it like to work for BioMarin?
Great people and a fun place to work BioMarin is a good company, the people work very hard and there is a wide variety of people with impressive skills. It is easy to talk to people and the culture is largely positive. I was an RA in the research department, working on developing drug screening assays.
What drugs does BioMarin make?
- VOXZOGO™ (vosoritide)
- PALYNZIQ® (pegvaliase-pqpz) Injection.
- Brineura® (cerliponase alfa)
- Vimizim® (elosulfase alfa)
- Kuvan® (sapropterin dihydrochloride)
- Naglazyme® (galsulfase)
- Aldurazyme® (laronidase)
Is BioMarin a takeover target?
BioMarin BMRN has been on the takeover radar for quite some time now. The company’s portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRN’s prospects significantly.
Who bought biotech?
Kerry buys 2 biotech companies for more than $226M.
Who will acquire BioMarin?
Total BioMarin’s value per share based on the DCF model is $126. BioMarin could become an acquisition target. The possible buyers are Sanofi, Roche, and Vertex.